ambossIconambossIcon

Stiff person syndrome

Last updated: September 6, 2019

Summarytoggle arrow icon

Stiff person syndrome (SPS) is a rare disorder that manifests with progressive muscle stiffness and rigidity. It is caused by an autoimmune process in which antibodies are formed against glutamic acid decarboxylase (GAD) or another protein in the gamma-aminobutyric acid (GABA) synthesis pathway. This leads to reduced levels of GABA, which then causes loss of CNS inhibition and increasing muscle stiffness. SPS is associated with autoimmune disorders (particularly type 1 diabetes mellitus). Less commonly, it occurs as a paraneoplastic process. Treatment of SPS consists of symptomatic treatment with benzodiazepines and muscle relaxants as well as immune modulation therapy with IVIG and immunosuppressants. Prognosis is poor, with most patients experiencing progressive gait disorders and disability.

Etiologytoggle arrow icon

References:[1]

Pathophysiologytoggle arrow icon

Anti-GAD antibodies → decreased GAD → decreased GABA → loss of CNS inhibition → increased muscle tone and rigidity

References:[1]

Clinical featurestoggle arrow icon

  • Generalized increase in skeletal muscle rigidity (hands, feet, and face remain unaffected); particularly in the muscles of the proximal extremities, neck and back.
  • Progressive rigidity may lead to lumbar or cervical hyperlordosis as well as gait abnormalities that may, in turn, cause falls and fractures.
  • Episodic painful muscle spasms triggered by external (e.g., noise) and internal (e.g., emotional upset) stimuli
  • Partial SPS: disease variant in which symptoms are limited to one extremity

References:[1]

Diagnosistoggle arrow icon

References:[1][2]

Treatmenttoggle arrow icon

Curative

  • For suspected paraneoplastic etiology: identification of the tumor and treatment!

Symptomatic

References:[1]

Icon of a lock3 free articles left this month

Start a 5-day free trial or sign up for unlimited access.
 Evidence-based content, created and peer-reviewed by clinicians. Read the disclaimer